Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Psoriatic Arthritis | Unmet Need | US/EU | 2024

Login to access report north_east
Contact sales account_box

TNF-alpha inhibitors remain the primary choice for psoriatic arthritis (PsA) after conventional DMARD failure, howeverbut competing biologics such as IL-17 inhibitors (Cosentyx, Taltz, Bimzelx), IL-12/23 inhibitors (Stelara), IL-23 inhibitors (Tremfya, Skyrizi), and targeted oral therapies such as PDE4 inhibitors and selective JAK inhibitors (Otezla, Xeljanz, Rinvoq) are increasingly challenging the dominance of TNF-alpha inhibitors in treating PsA. Moreover, many patients do not respond adequately to these agents, necessitating alternative treatment strategies. Thus, rRecognizing gaps in PsA treatment and focusing on product differentiation may play a crucial role in an agent’s success in this competitive PsA space. This report outlines key unmet needs and offers tools for strategic decision-making in the PsA therapy market.

QUESTIONS ANSWERED

  • How do current therapies perform on key treatment drivers and goals for PsA?
  • When considering Humira, Cosentyx, Taltz, Otezla, Rinvoq, Bimzelx, Skyrizi, and others wWhich drug attributes are key influencers, which have limited impact, and which are hidden opportunities in PsA?
  • What are the prevailing areas of unmet need and opportunity in the PsA market?
  • What trade-offs across key drug attributes and price are acceptable to rheumatologists and dermatologists for a hypothetical new PsA drug?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 31 European rheumatologists and dermatologists fielded in DecemberFebruary 2024

Key companies: AbbVie, Amgen, UCB, Pfizer, Johnson & Johnson Innovative Medicine, Novartis, Eli Lilly

Key drugs: Humira, Cosentyx, Taltz, SkyriziStelara, BimzelxTremfya, Otezla, Rinvoq

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
north_east
Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
north_east
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
north_east
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
north_east
Report
Thyroid Eye Disease – Executive Insights – Thyroid Eye Disease | Executive Insights (US)
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east